In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi-Aventis, BMS, Apotex in deal to settle Plavix suit

Executive Summary

Bristol-Myers Squibb, Sanofi-Aventis, and Apotex Inc. entered an agreement to settle a suit filed by Apotex regarding the validity and enforceability of a patent for Plavix (clopidogrel bisulfate), known as "the 265." The blockbuster blood thinning agent was developed by S-A--which sells the drug outside the US--and is sold within the US by BMS.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Marketing (Licensing)

Related Companies